Other Events ·
On June 10, 2026, stockholders approved an amendment to the Certificate of Incorporation increasing authorized common…
SNSESensei Biotherapeutics, Inc.
On June 10, 2026, stockholders approved an amendment to the Certificate of Incorporation increasing authorized common stock from 12.5 million to 300 million shares. Stockholders also approved the issuance of common stock upon conversion of Series B Non-Voting Convertible Preferred Stock, which will result in a change of control and exceed 20% of outstanding shares. Additionally, the company adopted a 2026 Equity Incentive Plan with an initial reserve of 2,671,981 shares (plus up to 311,164 shares from the 2021 plan) and a 2026 Employee Stock Purchase Plan with an initial reserve of 267,198 shares. Both plans include automatic annual increases through 2036. Sensei Biotherapeutics, Inc. is a biotechnology company that develops therapeutic treatments.